Melanoma Institute Australia and Cancer Council Australia are conducting a review of the clinical practice guidelines for the diagnosis and management of melanoma. The second phase is now available for review, by clinicians and the community, until 29 August 2025.
The pre-surgery use of combination immunotherapy as frontline treatment for high risk melanoma is now listed on the Pharmaceutical Benefits Scheme (PBS) and subsidised for all Australian patients.
Prestigious National Health and Medical Research Council (NHMRC) grants have been awarded for two clinical trials aiming to improve the accuracy of skin cancer diagnosis in Australia.
Read more about MIA clinicians and researchers in Chicago for ASCO25 - the American Society of Clinical Oncology Annual Meeting - to share latest research and clinical trial results with international colleagues.
Three studies led by researchers at Melanoma Institute Australia (MIA) are paving the way for less surgical and drug intervention for early stage melanoma patients.
The NHMRC grant will enable MIA to lead an international clinical trial aiming to safely reduce surgery for high risk Stage III melanoma patients who have had a good response to neoadjuvant immunotherapy.
A study has been released investigating the effectiveness of a Melanoma Care Program for patients with early-stage melanoma with varying degrees of fear of cancer recurrence after treatment of their primary melanoma.
The extensive global use of MIA’s online tool for estimating the risk of nodal metastasis in newly diagnosed melanoma patients has prompted an international study to validate its accuracy & improve its precision across diverse populations worldwide.
MIA researchers and clinicians attended the World Congress of Melanoma, held in conjunction with the EADO Congress, in Athens.
MIA researcher Dr Rebecca Simpson has been awarded a CINSW 2024 Early Career Fellowship which supports early & mid-career researchers through the development of research & leadership skills & innovative approaches to research.
